We’re thrilled to welcome Akoya Biosciences to the Quanterix Family. Read our latest press release to learn more about our acquisition of Akoya Biosciences and what it means for the future: bit.ly/3Grnht4

Quanterix experts Diana Caracino and Adam Shepro recently attended ELRIG’s USA Forum on #Neuroimmunology in Drug Discovery in Boston, MA, which highlighted the latest advancements in understanding the role of neuroimmune cells in neurological diseases.

Attending AAIC 2025? Let’s connect and explore how we can support your research. Learn more: bit.ly/3Gsdm6x #AAIC2025 #alzheimersdisease #biomarkers

Recent preclinical studies continue to demonstrate the utility of Simoa® #biomarkers in animal models of #neurodegeneration. Aeran et al.: lnkd.in/eE2-BMQP Mckean et al.: lnkd.in/exc2bhTV

Tau, a key protein in neurodegenerative diseases, remains a critical biomarker in understanding AD. Recent advancements in Tau biomarker research are breaking new ground in early diagnosis, prognosis, and treatment monitoring. Learn more: quanterix.com/whitepapers-ap…

AAIC® is just a few weeks away! Visit us at our booth #1510 to experience interactive demos of our latest biomarker detection instruments, a photo op with our giant TAU display, prize giveaways, and more: quanterix.com/conferences/al… #AlzheimersDisease #AlzheimersResearch

The Simoa® IL-12 p70 Advantage PLUS Assay enables femtogram-level detection on the HD-X system, providing high-resolution, reproducible immune data. Learn more: quanterix.com/simoa-assay-ki…

The brain-derived tau (BD-Tau) assay was recently evaluated in this multi-cohort study as a potential biomarker of treatment effect in AD and FTD patients receiving an anti-tau drug. Learn more: alz-journals.onlinelibrary.wiley.com/doi/full/10.10…

79% of scientists and researchers recently polled believe that p-tau 217 holds the most promise for advancing early detection of AD in the next 5 years. Learn how we're advancing AD pathology detection with the Simoa® ALZpath p-Tau217 Assay: quanterix.com/advancing-alzh…

AAIC® is this Sunday, are you ready? Visit us at our booth #1510 to experience interactive demos of our latest biomarker detection instruments, a photo op with our giant TAU display, prize giveaways, and more: quanterix.com/conferences/al… #AlzheimersDisease #AlzheimersResearch

Want to explore how p-Tau 205 offers unique insights into late-stage tau pathology? Our quick-reference fact sheet highlights p-Tau 205’s role in tracking NFT formation and disease progression—independent of amyloid pathology. Download now: quanterix.com/whitepapers-ap…

📍We’ve landed at AAIC 2025! Come find us at Booth #1510 for a photo-op with our life-size microtubule. #AAIC2025 #alzheimersdisease

Explore how a leading research team, led by Dr. Nicholas Ashton at Banner Health, leveraged Quanterix’s Homebrew model to develop a novel NPTX2 assay—offering critical insights into synaptic dysfunction in #neurodegenerative disease. Watch Part 1 now: youtu.be/SuyINdKMbiQ

A recent longitudinal study evaluated whether repeated plasma p-Tau 217 measurements can capture clinical heterogeneity among amyloid-positive individuals. Read now: alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Join Quanterix at the European Committee for Treatment & Research of MS (ECTRIMS) from September 24-26, 2025 in Barcelona, Spain. Learn more: bit.ly/3USTOvq

p-Tau 212 is transforming Alzheimer’s disease research and diagnostics. Download our fact sheet to discover how: bit.ly/3JaaHiU

In this next video interview with Applied Clinical Trials, Michael Miller, Chief Operating Officer at Quanterix, highlights #neurology and #oncology as two therapeutic areas experiencing major advances from biomarker integration. Watch now: bit.ly/45fiqVl

Looking to acheive highly selective, antibody-free detection of α-synuclein aggregates? Read the full study: pubs.rsc.org/en/content/art…

Quanterix & Akoya will be exhibiting together at Biomarkers & Precision Medicine UK! Sep 30 – Oct 1, 2025 London, UK Join us for an immersive event now in its 20th year, spotlighting the latest trends and tools in biomarker research. Learn more: bit.ly/4mbAB4i

In this next video with Applied Clinical Trials, Michael Miller outlines key technical and regulatory considerations for clinical operations professionals integrating biomarkers into studies. Watch now: appliedclinicaltrialsonline.com/view/clinical-…